TOP > 外国特許検索 > ACUTE RENAL FAILURE-SPECIFIC BIOMARKER, ACUTE RENAL FAILURE DIAGNOSIS METHOD, ACUTE RENAL FAILURE TEST KIT, ANIMAL TREATMENT METHOD AND ACUTE RENAL FAILURE MEDICATION

ACUTE RENAL FAILURE-SPECIFIC BIOMARKER, ACUTE RENAL FAILURE DIAGNOSIS METHOD, ACUTE RENAL FAILURE TEST KIT, ANIMAL TREATMENT METHOD AND ACUTE RENAL FAILURE MEDICATION NEW

外国特許コード F210010297
整理番号 S2018-1076-C0
掲載日 2021年1月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP039227
国際公開番号 WO 2020071518
国際出願日 令和元年10月4日(2019.10.4)
国際公開日 令和2年4月9日(2020.4.9)
優先権データ
  • 特願2018-188746 (2018.10.4) JP
発明の名称 (英語) ACUTE RENAL FAILURE-SPECIFIC BIOMARKER, ACUTE RENAL FAILURE DIAGNOSIS METHOD, ACUTE RENAL FAILURE TEST KIT, ANIMAL TREATMENT METHOD AND ACUTE RENAL FAILURE MEDICATION NEW
発明の概要(英語) Provided is a biomarker capable of specifically diagnosing acute renal failure. The acute renal failure-specific biomarker is miRNA which is primarily present in blood. The miRNA is miRNA-5100. Furthermore, it is possible to use this miRNA-5100 as a method for diagnosing acute renal failure. When making a diagnosis, acute renal failure is diagnosed when miRNA-5100 expression in the blood decreases. As a kit for testing for acute renal failure, it is possible to include a reagent which measures miRNA-5100.
従来技術、競合技術の概要(英語) BACKGROUND ART
Acute renal failure (Acute kidney injury, AKI) is, the infectious disease, medication, such as after surgery and acute renal dysfunction occurs, are largely responsible for the prognosis of a patient's life. Acute renal failure (AKI) is, in a short period of several hours to several days is reduced renal function rapidly in a disease. Urine excretion of waste products from unavailable, or to overflow. Dialysis and may be required.
Conventional, acute renal failure (Kidney Disease: Improving Global Outcomes) KDIGO diagnostic guidelines are provided. This KDIGO classification, urine and serum creatinine Acute renal failure is increased based on the decrease in the amount has been diagnosed.
Specifically, (KDIGO for acute renal failure diagnosis guideline, AKI (stage) of the classification stage, defined by any of the following: one or more serum creatinine value within 1. 48 to 0.3mg/dl to increase the serum creatinine value within the previous 2. has been found that 7 or 1.5 times or more the expected base value if there is an increase in the urine over a period of time 3. 6 0.5ml/kg/amount is reduced to
However, this reference has already been missed in the timing of therapeutic intervention in many cases. For this reason, the development of a biomarker for acute renal failure has been desired.
Incidentally, in recent years, a variety (microRNA, micro RNA) miRNA involved in the disease, early diagnosis of disease is effective as a biomarker has been reported. Referring to Patent Document 1, as an example of a conventional biomarker, chronic diabetic status of the indication of the miRNA is described.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JICHI MEDICAL UNIVERSITY
  • 発明者(英語)
  • MORISHITA, Yoshiyuki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、「問合せ先」までご連絡ください。

PAGE TOP

close
close
close
close
close
close